Metabolic Therapy at the Crossroad: How to Optimize Myocardial Substrate Utilization?

Trends in Cardiovascular Medicine

Volumn 19, Issue 6, 2009, Pages 201-207

  Kolwicz Jr , Stephen C ^a   Tian, Rong ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD36 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCAGON LIKE PEPTIDE; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA;

CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DRUG MECHANISM; ENERGY METABOLISM; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; HEART FAILURE; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOMEGALY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; ENERGY METABOLISM; FATTY ACIDS; GENE THERAPY; GENOTYPE; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; PHENOTYPE;

EID: 77649088425     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2009.12.005     Document Type: Review

References (72)

1. Aasum E., Belke D.D., Severson D.L., et al. Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol 283 (2002) H949-H957
2. Aasum E., Hafstad A.D., Severson D.L., and Larsen T.S. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52 (2003) 434-441
3. Abel E.D., Kaulbach H.C., Tian R., et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 104 (1999) 1703-1714
4. Allard M.F., Henning S.L., Wambolt R.B., et al. Glycogen metabolism in the aerobic hypertrophied rat heart. Circulation 96 (1997) 676-682
5. Arany Z., He H., Lin J., et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 1 (2005) 259-271
6. Arany Z., Novikov M., Chin S., et al. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A 103 (2006) 10086-10091
7. Arikawa E., Ma R.C., Isshiki K., et al. Effects of insulin replacements, inhibitors of angiotensin, and PKCbeta's actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. Diabetes 56 (2007) 1410-1420
8. Ashrafian H., Frenneaux M.P., and Opie L.H. Metabolic mechanisms in heart failure. Circulation 116 (2007) 434-448
9. Augustus A.S., Buchanan J., Park T.S., et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 281 (2006) 8716-8723
10. Barger P.M., and Kelly D.P. Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci 318 (1999) 36-42
11. Barouch L.A., Berkowitz D.E., Harrison R.W., et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108 (2003) 754-759
12. Belke D.D., Larsen T.S., Gibbs E.M., and Severson D.L. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 279 (2000) E1104-E1113
13. Bersin R.M., and Stacpoole P.W. Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am Heart J 134 (1997) 841-855
14. Boudina S., Sena S., Theobald H., et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56 (2007) 2457-2466
15. Buchanan J., Mazumder P.K., Hu P., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146 (2005) 5341-5349
16. Buttrick P.M., Kaplan M., Leinwand L.A., and Scheuer J. Alterations in gene expression in the rat heart after chronic pathological and physiological loads. J Mol Cell Cardiol 26 (1994) 61-67
17. Campbell F.M., Kozak R., Wagner A., et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 277 (2002) 4098-4103
18. Carley A.N., Semeniuk L.M., Shimoni Y., et al. Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am J Physiol Endocrinol Metab 286 (2004) E449-E455
19. Chess D.J., Khairallah R.J., O'Shea K.M., et al. A high fat diet increases adiposity but maintains mitochondrial oxidative enzymes without affecting development of heart failure with pressure overload. Am J Physiol Heart Circ Physiol 297 (2009) H1585-H1593
20. D'Alessio D.A., Kahn S.E., Leusner C.R., and Ensinck J.W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93 (1994) 2263-2266
21. Dyck J.R., Hopkins T.A., Bonnet S., et al. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 114 (2006) 1721-1728
22. Finck B.N., Lehman J.J., Leone T.C., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109 (2002) 121-130
23. Fisher D.J. Oxygenation and metabolism in the developing heart. Semin Perinatol 8 (1984) 217-225
24. Hafstad A.D., Khalid A.M., Hagve M., et al. Cardiac peroxisome proliferator-activated receptor-alpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss. Cardiovasc Res 83 (2009) 519-526
25. Hafstad A.D., Khalid A.M., How O.J., et al. Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice. Am J Physiol Endocrinol Metab 292 (2007) E1288-E1294
26. How O.J., Aasum E., Kunnathu S., et al. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am J Physiol Heart Circ Physiol 288 (2005) H2979-H2985
27. How O.J., Larsen T.S., Hafstad A.D., et al. Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch Physiol Biochem 113 (2007) 211-220
28. Ingwall J.S. ATP and the heart (2002), Kluwer Academic, Boston
29. Irie H., Krukenkamp I.B., Brinkmann J.F., et al. Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids. Proc Natl Acad Sci U S A 100 (2003) 6819-6824
30. Katz E.B., Stenbit A.E., Hatton K., et al. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 377 (1995) 151-155
31. Koonen D.P., Febbraio M., Bonnet S., et al. CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation 116 (2007) 2139-2147
32. Kuang M., Febbraio M., Wagg C., et al. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109 (2004) 1550-1557
33. Kudo N., Barr A.J., Barr R.L., et al. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270 (1995) 17513-17520
34. Labinskyy V., Bellomo M., Chandler M.P., et al. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. J Pharmacol Exp Ther 321 (2007) 165-171
35. Lehman J.J., Barger P.M., Kovacs A., et al. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106 (2000) 847-856
36. Liao R., Jain M., Cui L., et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 106 (2002) 2125-2131
37. Lionetti V., Linke A., Chandler M.P., et al. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res 66 (2005) 454-461
38. Loichot C., Jesel L., Tesse A., et al. Deletion of peroxisome proliferator-activated receptor-alpha induces an alteration of cardiac functions. Am J Physiol Heart Circ Physiol 291 (2006) H161-H166
39. Lopaschuk G.D., Belke D.D., Gamble J., et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213 (1994) 263-276
40. Luptak I., Balschi J.A., Xing Y., et al. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 112 (2005) 2339-2346
41. Luptak I., Shen M., He H., et al. Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J Clin Invest 117 (2007) 1432-1439
42. Mazumder P.K., O'Neill B.T., Roberts M.W., et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53 (2004) 2366-2374
43. McQueen A.P., Zhang D., Hu P., et al. Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density. J Mol Cell Cardiol 39 (2005) 882-892
44. Morgan E.E., Rennison J.H., Young M.E., et al. Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am J Physiol Heart Circ Physiol 290 (2006) H1899-H1904
45. Nahrendorf M., Spindler M., Hu K., et al. Creatine kinase knockout mice show left ventricular hypertrophy and dilatation, but unaltered remodeling post-myocardial infarction. Cardiovasc Res 65 (2005) 419-427
46. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 356 (2007) 1140-1151
47. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004) 962-965
48. O'Donnell J.M., Fields A.D., Sorokina N., and Lewandowski E.D. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J Mol Cell Cardiol 44 (2008) 315-322
49. Okere I.C., Young M.E., McElfresh T.A., et al. Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension. Hypertension 48 (2006) 1116-1123
50. Opie L.H. Heart physiology : from cell to circulation (2004), Lippincott Williams & Wilkins, Philadelphia
51. Poornima I., Brown S.B., Bhashyam S., et al. Chronic glucagon-like peptide-1 (GLP-1) infusion sustains LV systolic function and prolongs survival in the spontaneously hypertensive heart failure prone rat. Circ Heart Fail 1 (2008) 153-160
52. Razeghi P., Young M.E., Alcorn J.L., et al. Metabolic gene expression in fetal and failing human heart. Circulation 104 (2001) 2923-2931
53. Rennison J.H., McElfresh T.A., Chen X., et al. Prolonged exposure to high dietary lipids is not associated with lipotoxicity in heart failure. J Mol Cell Cardiol 46 (2009) 883-890
54. Rupp H., and Vetter R. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure. Br J Pharmacol 131 (2000) 1748-1756
55. Russell L.K., Mansfield C.M., Lehman J.J., et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 94 (2004) 525-533
56. Sambandam N., Morabito D., Wagg C., et al. Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 290 (2006) H87-H95
57. Saupe K.W., Spindler M., Tian R., and Ingwall J.S. Impaired cardiac energetics in mice lacking muscle-specific isoenzymes of creatine kinase. Circ Res 82 (1998) 898-907
58. Sena S., Hu P., Zhang D., et al. Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. J Mol Cell Cardiol 46 (2009) 910-918
59. Sharma V., Dhillon P., Wambolt R., et al. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat. Am J Physiol Heart Circ Physiol 294 (2008) H1609-H1620
60. Sokos G.G., Nikolaidis L.A., Mankad S., et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12 (2006) 694-699
61. Stenbit A.E., Katz E.B., Chatham J.C., et al. Preservation of glucose metabolism in hypertrophic GLUT4-null hearts. Am J Physiol Heart Circ Physiol 279 (2000) H313-H318
62. Tian R. Transcriptional regulation of energy substrate metabolism in normal and hypertrophied heart. Curr Hypertens Rep 5 (2003) 454-458
63. Tian R., and Abel E.D. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 103 (2001) 2961-2966
64. Tuunanen H., Engblom E., Naum A., et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 114 (2006) 2130-2137
65. Vitale C., Wajngaten M., Sposato B., et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25 (2004) 1814-1821
66. Watanabe K., Fujii H., Takahashi T., et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 275 (2000) 22293-22299
67. Wende A., Pires K.M., Wayment B., et al. Pyruvate dehydrogenase kinase 4 (PDK4) deficiency does not impair the cardiac metabolic or contractile response to pressure overload hypertrophy (2009), American Heart Association Scientific Sessions, Orlando, Florida 3889
68. Witteles R.M., Tang W.H., Jamali A.H., et al. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol 44 (2004) 78-81
69. Yan J., Young M.E., Cui L., et al. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 119 (2009) 2818-2828
70. Yang J., Sambandam N., Han X., et al. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 100 (2007) 1208-1217
71. Young M.E., Laws F.A., Goodwin G.W., and Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276 (2001) 44390-44395
72. Zhao G., Jeoung N.H., Burgess S.C., et al. Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 294 (2008) H936-H943